# A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors

> **NCT02593786** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 58 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02593786
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-07
- **Primary completion:** 2021-09-27
- **Final completion:** 2021-09-27
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2022-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02593786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02593786, "A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02593786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*